IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Endo International Plc And Encourages Investors With Losses To Contact The Firm

Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Endo International plc ("Endo" or the "Company") (Nasdaq: ENDP) concerning possible violations of federal securities laws between September 28, 2015 and November 2, 2016 inclusive (the "Class Period"). Investors, who purchased or otherwise acquired shares during the Class Period, are encouraged to contact the firm in advance of the January 6, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Endo made false and/or misleading statements and/or failed to disclose that: the Company's subsidiary, Par Pharmaceutical, colluded with several of its industry peers to fix generic drug prices; that the foregoing conduct constituted a violation of federal antitrust laws; that Endo's revenues during the Class Period were partially the result of illegal conduct; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. On November 3, 2016, Bloomberg News reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Par Pharmaceutical, to determine whether they unlawfully colluded with each other to fix generic drug prices.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds